Literature DB >> 10728805

Liver transplantation.

J Neuberger1.   

Abstract

Since the first human liver transplant done in 1963, the procedure has become a routine procedure with an excellent outcome in terms both of quality and of length of survival. The development and introduction into clinical practice of a variety of immunosuppressive agents has given the clinician a bewildering array of therapeutic options but with a lack of evidence on which to select for optimal immunosuppression. Tolerance can be reliably achieved in some animal transplants but remains to be achieved in humans. One of the major challenges facing the transplant community is the shortage of donor organs: imaginative approaches to overcome this problem include more effective use of marginal donor livers, splitting livers and development of living related transplants. While advances have been made in the field of xenotransplantation, there remain many hurdles to be overcome before this approach can be introduced into human transplantation. In the meanwhile, there are difficulties in determining the optimal criteria for listing patients for transplantation and for treating some of the complications arising after transplantation such as recurrence of disease and complications of immunosuppression, e.g. renal failure, malignancy and vascular disease.

Entities:  

Mesh:

Year:  2000        PMID: 10728805     DOI: 10.1016/s0168-8278(00)80426-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma.

Authors:  Zhijun Zhu
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 2.  Immune monitoring post liver transplant.

Authors:  Siddharth Sood; Adam G Testro
Journal:  World J Transplant       Date:  2014-03-24

3.  Laparoscopic left hemicolectomy in a patient with cirrhosis scheduled for liver transplantation.

Authors:  O Goletti; A Battini; A Capria; G Zocco; E Cavina
Journal:  Surg Endosc       Date:  2003-05       Impact factor: 4.584

4.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

5.  Bone marrow engraftment in a rodent model of chemical carcinogenesis but no role in the histogenesis of hepatocellular carcinoma.

Authors:  H Ishikawa; K Nakao; K Matsumoto; D Nishimura; T Ichikawa; K Hamasaki; K Eguchi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

Review 6.  Different approaches for transformation of mesenchymal stem cells into hepatocyte-like cells.

Authors:  Afsoon Afshari; Sara Shamdani; Georges Uzan; Sina Naserian; Negar Azarpira
Journal:  Stem Cell Res Ther       Date:  2020-02-07       Impact factor: 6.832

7.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis.

Authors:  Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Francoise Poirier; Francesco P Russo; John P Iredale; Christopher Haslett; Kenneth J Simpson; Tariq Sethi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

8.  Liver-enriched transcription factors are critical for the expression of hepatocyte marker genes in mES-derived hepatocyte-lineage cells.

Authors:  Pakpoom Kheolamai; Alan J Dickson
Journal:  BMC Mol Biol       Date:  2009-04-23       Impact factor: 2.946

9.  Immunological aspects in late phase of living donor liver transplant patients: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity.

Authors:  Shugo Mizuno; Yuichi Muraki; Kaname Nakatani; Akihiro Tanemura; Naohisa Kuriyama; Ichiro Ohsawa; Yoshinori Azumi; Masashi Kishiwada; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata; Norihiko Yamamoto; Tomomi Yamada; Katsuya Shiraki; Yoshiyuki Takei; Tsutomu Nobori; Masahiro Okuda; Shuji Isaji
Journal:  Clin Dev Immunol       Date:  2013-09-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.